TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma
The Journal of Clinical Endocrinology & Metabolism · 13.04.2023 · 108 (5) · 1132-1142
DOI: 10.1210/clinem/dgac677 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 26.11.2022. Verfasst von Camilo Jimenez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Pheochromocytoma, Paraganglioma, Brain Neoplasms, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Context
Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors. Metastases develop in 15% to 20%. The American Joint Committee on Cancer (AJCC) established inaugural guidelines for PPGL tumor-node-metastasis (TNM) staging.
Objective
The objective of this analysis is to investigate the associations between TNM staging and overall survival (OS).
Methods
We retrospectively applied the TNM staging at the time of diagnosis of the primary tumor. The primary outcome was OS. Unadjusted survival rates were estimated by the Kaplan–Meier method. Cox proportional hazards regression models were used to evaluate the associations between OS and covariates of interest.
Results
The study included 458 patients. Median OS was 18.0 (95% CI, 15.6-not reached) years. At diagnosis, 126 (27.5%) tumors were stage I, 213 (46.5%) were stage II, 47 (10.3%) were stage III, and 72 (15.7%) were stage IV. The 10-year OS probabilities were 0.844 (95% CI, 0.768-0.928) for patients with stage I tumors, 0.792 (95% CI, 0.726-0.865) for stage II, 0.595 (95% CI, 0.435-0.813) for stage III, and 0.221 (95% CI, 0.127-0.384) for stage IV. Compared with stage I, the hazard ratios (HR) for death were 1.50 (0.87-2.57) for stage II, 2.85 (1.45-5.63) for stage III, and 8.88 (5.16-15.29) for stage IV (P < 0.001). Compared with patients with no germline mutations, those with RET 634/918 had better OS (HR: 0.28; 95% CI, 0.12-0.69). Other germline mutations, including SDHB, did not exhibit worse OS than patients with metastasis and sporadic disease.
Conclusion
OS rates correlated with the recently developed AJCC TNM staging and were not worse in hereditary disease. Stage IV disease exhibited a significantly shorter OS compared with stages I-III. Future staging systems could be adjusted to better separate stages I and II.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Endocrinology, San Vicente Fundación-Universidad de Antioquia, Medellin, Colombia.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Camilo Jimenez, Alejandro Roman Gonzalez, Steven G Waguespack
Zitieren
APA
Jimenez, C., Ma, J., Roman Gonzalez, A., Varghese, J., Zhang, M., Perrier, N., Habra, M. A., Graham, P., & Waguespack, S. G. (2023). TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. The Journal of Clinical Endocrinology & Metabolism, 108(5), 1132-1142. https://doi.org/10.1210/clinem/dgac677
Vancouver
Jimenez C, Ma J, Roman Gonzalez A, Varghese J, Zhang M, Perrier N, et al. TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. The Journal of Clinical Endocrinology & Metabolism. 2023;108(5):1132-1142. doi:10.1210/clinem/dgac677
BibTeX
@article{Jimenez2023,
author = {Jimenez, Camilo and Ma, Junsheng and Roman Gonzalez, Alejandro and Varghese, Jeena and Zhang, Miao and Perrier, Nancy and Habra, Mouhammed Amir and Graham, Paul and Waguespack, Steven G},
title = {TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {5},
pages = {1132--1142},
doi = {10.1210/clinem/dgac677}
}
EUVIMED